abstract |
A bispecific antibody has binding specificity for a marker common to all prostate cells on one arm of the antibody, and binding specificity for T cell marker CD3 on the other antibody arm. The combined specificities bring together a tumor cell and a T effector cell, whose specificity is reprogrammed to kill the tumor cell. Invitro studies showed that the bispecific antibody achieves a much greater level of cytotoxicity than either individual antibody alone. |